USA News Group News Commentary - Stanford researchers achieved complete diabetes reversal in mice using a combined blood stem cell and islet transplant that eliminates the need for insulin or ...

Pfizer said revenue should come in at the lower end of its guidance this year, and it expects less revenue in 2026 than in 2025, as the drugmaker's efforts to remake its business continue to play out.

U.S. lawsuits against Novo Nordisk and Eli Lilly alleging patients taking weight loss drugs lost some or all of their ...

Novo Nordisk can end the horror year of 2025 on a positive note. The EMA has issued a positive opinion on a higher Wegovy ...

Pfizer revised its revenue expectations for 2025 and detailed its guidance for 2026. Pfizer said revenue should come in at the lower end of its guidance this year, and it expects less revenue in 2026 ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it ...

The Indian judiciary did well not to let Novo Nordisk extend its exclusive right to sell semaglutide, marketed as Ozempic and ...

Pfizer on Tuesday forecast 2026 profit below Wall Street estimates as it expects a drop in sales of its COVID products and a ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Medications like Ozempic mimic a naturally occurring hormone called glucagon-like peptide-1, or GLP-1, which helps regulate blood sugar and appetite. GLP-1 is primarily secreted from the intestines, ...

I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...